IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer

Wei, Qingzhu; Zhou, Hui; Zhong, Ling; Shi, Long; Liu, Jianghuan; Qiao, Yanjiang; Zhao, Tong

doi:10.1016/j.humpath.2017.03.013

Cited by 20 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, the expression of IMP3 was predominantly in the cytoplasm. This is in accordance with numerous studies in which cytoplasmic immunostaining was observed (7,8,16,35). This is interpreted that IMP3 protein is present in the cytoplasm (39).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

Madawi

Sheikh

Riad

et al. 2020

Alexandria Dental Journal

View full text Add to dashboard Cite

INTRODUCTION: Salivary gland tumors (SGTs) are infrequent tumours accounting for 2-6.5% of all head and neck tumors. They show various clinical behaviours and different histological patterns resulting in a diagnostic dilemma. Insulin like growth factor II mRNA binding protein 3 (IMP3) is an oncofetal protein that plays an important role in tumor invasion and metastases. Several studies proved the prognostic role of IMP3 in different human cancers. However, its role in SGTs still needs to be confirmed. OBJECTIVES: To evaluate IMP3 immunoexpression in benign and malignant SGTs. MATERIALS AND METHODS: IMP3 expression was measured in 44 SGT cases (20 benign and 24 malignant) and 10 normal salivary gland tissues (NSGT). Immunohistochemical (IHC) staining was carried out by the Labeled Strept-Avidin Biotin complex method (LSAB). RESULTS: IMP3 expression was detected in NSGT as well as benign and malignant SGTs with different intensities. The Lowest expression levels were detected in NSGT, while the highest ones were detected in Malignant SGTs. CONCLUSION: IMP3 could be used as a diagnostic marker in SGTs.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Similar results were found in studies conducted on other tumors. Wei et al (35) detected high IMP3 expression in colorectal carcinomas and low expression in colorectal adenomas. Moreover, Senoo et al (36) found that IMP3 expression was higher in malignant intraductal papillary mucinous neoplasms than in their benign counterparts.…”

Section: Discussionmentioning

confidence: 98%

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

Madawi

Sheikh

Riad

et al. 2020

Alexandria Dental Journal

View full text Add to dashboard Cite

show abstract

“…The further study discovered that IGF2BP3 is the translation activator of IGF IImRNA, which relies on IGF II to drive the proliferation of leukemia cells [30]. IGF2BP3 is now thought to be a particular tumor biomarker in colorectal cancer as research progresses [31].…”

Section: Investigation Of Igf2bp3 Expression In Paadmentioning

confidence: 99%

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

Zhang

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Pancreatic adenocarcinoma (PAAD) has become the major cause of cancer-related deaths globally. The m6A (N6-methyladenosine) alteration plays a crucial function in carcinogenesis and tumor progression. The role of genes related to m6A and their expression level in pancreatic cancer is not identified yet. The objective of this research analysis is a demonstration of the m6A RNA methylation regulators based as biomarkers for the PAAD diagnosis. Methods. About 23 extensively reported m6A RNA methylation regulators were identified through the Cancer Genome Atlas (TCGA) database. This identification was based on consensus clustering analysis, protein-protein integration (PPI) analysis, risk prognostic model, Cox-regression analysis, String Spearman analysis, and LASSO Cox-regression. Results. Herein, we conclude that 23 m6A methylation regulators have a strong link with the clinical and molecular characteristics of PAAD. The three subgroups (1/2) of pancreatic adenocarcinoma were identified using the clustering of 23 m6A regulators. Subgroup cluster 2 had a lower survival rate than the subgroup of cluster 1, and the difference in grades between the two groups was substantial. An assessment was performed using the 23 reported m6A methylation regulators. Eight of these can be used as independent PAAD prognostic markers. The consequences of variable IGF2BP3 expression in PAAD were then investigated further. Conclusions. The key finding of this study was that the m6A methylation regulator gene has the main role in pancreatic tumors, and it may be used as a biomarker in the prognosis of the PAAD and for therapy purposes.

show abstract

“…A growing body of evidence shows that IGF2BP3 has shown its promising value on cancer therapy ( Lochhead et al, 2012 ; Hsu et al, 2015 ). Numerous cancers have been identified the overexpression of IGF2BP3 including lung cancer ( Findeis-Hosey and Xu, 2012 ), breast cancer ( Scott et al, 2018 ), colorectal cancer ( Wei et al, 2017 ; Xu et al, 2019 ), hepatocellular carcinoma ( Shaalan et al, 2018 ), pancreatic cancer ( Chen et al, 2019 ), glioblastoma and ovarian clear cell carcinoma ( Bi et al, 2016 ; Dutoit et al, 2018 ). IGF2BP3 is a carcinoembryonic protein that is highly expressed during embryogenesis, lowly expressed in adult tissues, and re-expressed in malignant tissues ( Palanichamy et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

IGF2BP3 May Contributes to Lung Tumorigenesis by Regulating the Alternative Splicing of PKM

Huang

Zhang

Jiang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

RNA binding proteins (RBPs) play a key role in genome regulation. Here we report the post-transcript regulation of IGF2BP3, which belongs to the insulin-like growth factor 2 mRNA binding protein family. We used iRIP-seq and RNA-seq to analyze the transcript regulation and alternative splicing on IGF2BP3 treated with overexpression cells and control. Overexpressed IGF2BP3 has broadly increased genes expression which involved in G-protein coupled receptor signaling pathway, positive regulation of cell proliferation, and signal transduction. IGF2BP3 regulated alternative splicing of multiple genes mainly clustered at response to hypoxia, negative regulation of transcription, and embryonic development. This study first provides alternative splicing analysis on transcription level of IGF2BP3 regulation, which laid the foundation for later research on IGF2BP3 critical functions.

show abstract

IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer

Cited by 20 publications

References 22 publications

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

IGF2BP3 May Contributes to Lung Tumorigenesis by Regulating the Alternative Splicing of PKM

Contact Info

Product

Resources

About